The global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The USA market for Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
Report Sample includes:
- Table of Contents
- List of Tables & Figures
- Charts
- Research Methodology
Get FREE Sample of this Report at https://www.24marketreports.com/report-sample/global-transthyretin-amyloid-cardiomyopathy-treatment-forecast-2023-2030-16
The China market for Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The Europe market for Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
Transthyretin Amyloidosis (ATTR) is a progressive and severe orphan disease. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of transthyretin amyloidosis (ATTR) that affects the heart and leads to restrictive cardiomyopathy and progressive heart failure. It is generally a rare, underdiagnosed, life-threatening disease.
This report aims to provide a comprehensive presentation of the global market for Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment. This report contains market size and forecasts of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment in global, including the following market information:
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Transthyretin Stabilizers Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment include Pfizer Inc, GlaxoSmithKline Plc, Eidos Therapeutics, Ionis Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Prothena Corporation Plc, Intellia Therapeutics, Inc and Corino Therapeutics, Inc, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Segment Percentages, by Type, 2022 (%)
Transthyretin Stabilizers
Nonsteroidal Anti-inflammatory Drugs (NSAID)
RNAi Therapy
Others
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Segment Percentages, by Application, 2022 (%)
Hereditary Transthyretin Amyloidosis (hATTR)
Wild Type Transthyretin Amyloidosis (wtATTR)
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
The Middle East and Africa (Middle East, Africa)
South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer Inc
GlaxoSmithKline Plc
Eidos Therapeutics
Ionis Pharmaceuticals, Inc
Alnylam Pharmaceuticals
Prothena Corporation Plc
Intellia Therapeutics, Inc
Corino Therapeutics, Inc
Outline of Major Chapters:
Chapter 1: Introduces the definition of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment, market overview.
Chapter 2: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market size in revenue.
Chapter 3: Detailed analysis of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
Get the Complete Report & TOC at https://www.24marketreports.com/life-sciences/global-transthyretin-amyloid-cardiomyopathy-treatment-forecast-2023-2030-16
CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170
Follow Us On linkedin :-https://www.linkedin.com/company/24-market-reports
Comentarios